Cenegermin, sold under the brand name Oxervate, also known as recombinant human nerve growth factor, is a recombinant form of human nerve growth factor.
[4] Cenegermin is a peripherally selective agonist of the tropomyosin receptor kinase A (TrkA) and low-affinity nerve growth factor receptor (p75NTR).
[5] It was approved for medical use in the European Union in July 2017,[5] and in the United States in 2018.
[4][6] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
[7] It is also known as human beta-nerve growth factor (beta-NGF)-(1-118) peptide (non-covalent dimer) produced in Escherichia coli.